Used in solid-phase peptide synthesis as a protected amino acid building block, particularly for incorporating constrained piperidine-derived structures into peptides. The Fmoc group allows for mild base-labile protection compatible with standard peptide coupling protocols. The cyclohexyl substituent adds hydrophobic character and conformational rigidity, which can enhance peptide stability, improve receptor selectivity, or modulate bioavailability in medicinal chemistry applications. Commonly employed in the development of peptidomimetics and bioactive compounds targeting CNS receptors and GPCRs.